E

Enzymatica AB (publ)
STO:ENZY

Watchlist Manager
Enzymatica AB (publ)
STO:ENZY
Watchlist
Price: 1.8 SEK 3.45% Market Closed
Market Cap: 436.9m SEK
Have any thoughts about
Enzymatica AB (publ)?
Write Note

Enzymatica AB (publ)
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Enzymatica AB (publ)
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
E
Enzymatica AB (publ)
STO:ENZY
Accounts Receivables
kr9.7m
CAGR 3-Years
-3%
CAGR 5-Years
-9%
CAGR 10-Years
5%
Calliditas Therapeutics AB
STO:CALTX
Accounts Receivables
kr222.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Camurus AB
STO:CAMX
Accounts Receivables
kr321.9m
CAGR 3-Years
50%
CAGR 5-Years
70%
CAGR 10-Years
N/A
S
Swedencare AB (publ)
STO:SECARE
Accounts Receivables
kr287.4m
CAGR 3-Years
59%
CAGR 5-Years
74%
CAGR 10-Years
N/A
Moberg Pharma AB (publ)
STO:MOB
Accounts Receivables
kr0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
I
InDex Pharmaceuticals Holding AB
STO:FLERIE
Accounts Receivables
kr700k
CAGR 3-Years
N/A
CAGR 5-Years
151%
CAGR 10-Years
N/A
No Stocks Found

Enzymatica AB (publ)
Glance View

Market Cap
436.9m SEK
Industry
Pharmaceuticals

Enzymatica AB engages in the research, development, and sale of medical technology products. The company is headquartered in Lund, Skane and currently employs 26 full-time employees. The company went IPO on 2011-06-14. The company researches, develops and registers enzyme-based health and wellbeing products. The firm uses a patented enzyme, Penzyme, a cold-adapted trypsin from deep sea cod. The enzyme is active at about 37 Celsius degree and decomposes disease-related proteins, counteracting viral and bacterial infections and supporting healing processes. The firm conducts clinical studies of ColdZyme Munspray, a cold medicine. The company operates such subsidiaries, as Enzymatica Care AB, Zymetech ehf, among others. Main shareholders of Enzymatica AB are Humea AB, Medi AB, and Nordic Consulting Group AB, among others. In November 2013, the Company established another subsidiary in the United States, Enzymatica North America Inc., responsible for future production and sale of veterinary products in the United States and Canada.

ENZY Intrinsic Value
1.83 SEK
Undervaluation 2%
Intrinsic Value
Price
E

See Also

What is Enzymatica AB (publ)'s Accounts Receivables?
Accounts Receivables
9.7m SEK

Based on the financial report for Sep 30, 2024, Enzymatica AB (publ)'s Accounts Receivables amounts to 9.7m SEK.

What is Enzymatica AB (publ)'s Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
5%

Over the last year, the Accounts Receivables growth was -9%. The average annual Accounts Receivables growth rates for Enzymatica AB (publ) have been -3% over the past three years , -9% over the past five years , and 5% over the past ten years .

Back to Top